Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023
As a leader in HIV innovation, Gilead will provide an update on its signature initiatives, key collaborations and share new scientific data from its HIV research and development programs.
- As a leader in HIV innovation, Gilead will provide an update on its signature initiatives, key collaborations and share new scientific data from its HIV research and development programs.
- Additional lenacapavir data presented at EACS 2023 will provide insight into the therapy’s resistance profile.
- The mental health outcomes reported by participants in BICSTaR over a two-year period will also be presented at EACS 2023.
- Mental health impairments can further increase the risk of negative health outcomes at every stage of the HIV care continuum.